Cargando…

Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

OBJECTIVE: Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjӧwall, Christopher, Bentow, Chelsea, Aure, Mary Ann, Mahler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136571/
https://www.ncbi.nlm.nih.gov/pubmed/30246032
http://dx.doi.org/10.1155/2018/1294680
_version_ 1783355026594332672
author Sjӧwall, Christopher
Bentow, Chelsea
Aure, Mary Ann
Mahler, Michael
author_facet Sjӧwall, Christopher
Bentow, Chelsea
Aure, Mary Ann
Mahler, Michael
author_sort Sjӧwall, Christopher
collection PubMed
description OBJECTIVE: Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric model approach for the assessment of disease activity and lupus nephritis. METHODS: Samples from 261 well-characterized SLE patients were tested using chemiluminescent immunoassays (CIA) for anti-dsDNA and anti-Ku antibodies as well as by anti-C1q antibody ELISA (Inova Diagnostics, USA). Of these SLE patients, 26.4% had lupus nephritis (LN) at the time of blood draw or had a history of LN, and modified SLE disease activity index-2K (SLEDAI) scores were used to assess disease activity. RESULTS: All three antibodies demonstrated higher prevalence and higher antibody levels in active versus inactive SLE patients and in LN versus non-LN patients. When oligoparametric analysis was performed, the likelihood of LN and patients with active disease increased with dual and triple positivity. CONCLUSIONS: Anti-dsDNA and anti-C1q antibodies are useful tools to identify disease activity and/or renal involvement in SLE patients. In addition, the combination of those antibodies in a two-parametric score might improve the clinical utility of those markers.
format Online
Article
Text
id pubmed-6136571
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61365712018-09-23 Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus Sjӧwall, Christopher Bentow, Chelsea Aure, Mary Ann Mahler, Michael J Immunol Res Research Article OBJECTIVE: Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric model approach for the assessment of disease activity and lupus nephritis. METHODS: Samples from 261 well-characterized SLE patients were tested using chemiluminescent immunoassays (CIA) for anti-dsDNA and anti-Ku antibodies as well as by anti-C1q antibody ELISA (Inova Diagnostics, USA). Of these SLE patients, 26.4% had lupus nephritis (LN) at the time of blood draw or had a history of LN, and modified SLE disease activity index-2K (SLEDAI) scores were used to assess disease activity. RESULTS: All three antibodies demonstrated higher prevalence and higher antibody levels in active versus inactive SLE patients and in LN versus non-LN patients. When oligoparametric analysis was performed, the likelihood of LN and patients with active disease increased with dual and triple positivity. CONCLUSIONS: Anti-dsDNA and anti-C1q antibodies are useful tools to identify disease activity and/or renal involvement in SLE patients. In addition, the combination of those antibodies in a two-parametric score might improve the clinical utility of those markers. Hindawi 2018-08-30 /pmc/articles/PMC6136571/ /pubmed/30246032 http://dx.doi.org/10.1155/2018/1294680 Text en Copyright © 2018 Christopher Sjӧwall et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sjӧwall, Christopher
Bentow, Chelsea
Aure, Mary Ann
Mahler, Michael
Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title_full Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title_fullStr Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title_full_unstemmed Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title_short Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
title_sort two-parametric immunological score development for assessing renal involvement and disease activity in systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136571/
https://www.ncbi.nlm.nih.gov/pubmed/30246032
http://dx.doi.org/10.1155/2018/1294680
work_keys_str_mv AT sjöwallchristopher twoparametricimmunologicalscoredevelopmentforassessingrenalinvolvementanddiseaseactivityinsystemiclupuserythematosus
AT bentowchelsea twoparametricimmunologicalscoredevelopmentforassessingrenalinvolvementanddiseaseactivityinsystemiclupuserythematosus
AT auremaryann twoparametricimmunologicalscoredevelopmentforassessingrenalinvolvementanddiseaseactivityinsystemiclupuserythematosus
AT mahlermichael twoparametricimmunologicalscoredevelopmentforassessingrenalinvolvementanddiseaseactivityinsystemiclupuserythematosus